Notoginsenoside R1-loaded mesoporous silica nanoparticles targeting the site of injury through inflammatory cells improves heart repair after myocardial infarction

Han Li,Jing Zhu,Yan-wu Xu,Fang-fang Mou,Xiao-li Shan,Qiang-li Wang,Bao-nian Liu,Ke Ning,Jia-jia Liu,Ya-chao Wang,Jin-xia Mi,Xiaohui Wei,Shui-jin Shao,Guo-hong Cui,Rong Lu,Hai-dong Guo

DOI: https://doi.org/10.1016/j.redox.2022.102384

IF: 11.4

2022-06-25

Redox Biology

Abstract:Notoginsenoside R1 (NGR1) is the main monomeric component extracted from the dried roots and rhizomes of Panax notoginseng, and exerts pharmacological action against myocardial infarction (MI). Owing to the differences in compound distribution, absorption, and metabolism in vivo , exploring a more effective drug delivery system with a high therapeutic targeting effect is crucial. In the early stages of MI, CD11b-expressing monocytes and neutrophils accumulate at infarct sites. Thus, we designed a mesoporous silica nanoparticle-conjugated CD11b antibody with loaded NGR1 (MSN-NGR1-CD11b antibody), which allowed NGR1 precise targeted delivery to the heart in a noninvasively manner. By increasing targeting to the injured myocardium, intravenous injection of MSN-NGR1-CD11b antibody nanoparticle in MI mice improved cardiac function and angiogenesis, reduced cell apoptosis, and regulate macrophage phenotype and inflammatory factors and chemokines. In order to further explore the mechanism of NGR1 protecting myocardium, cell oxidative stress model and oxygen-glucose deprivation (OGD) model were established. NGR1 protected H9C2 cells and primary cardiomyocytes against oxidative injury induced by H 2 O 2 and OGD treatment. Further network pharmacology and molecular docking analyses suggested that the AKT, MAPK and Hippo signaling pathways were involved in the regulation of NGR1 in myocardial protection. Indeed, NGR1 could elevate the levels of p-Akt and p-ERK, and promote the nuclear translocation of YAP. Furthermore, LY294002 (AKT inhibitor), U0126 (ERK1/2 inhibitor) and Verteporfin (YAP inhibitor) administration in H9C2 cells indicated the involvement of AKT, MAPK and Hippo signaling pathways in NGR1 effects. Meanwhile, MSN-NGR1-CD11b antibody nanoparticles enhanced the activation of AKT and MAPK signaling pathways and the nuclear translocation of YAP at the infarcted site. Our research demonstrated that MSN-NGR1-CD11b antibody nanoparticle injection after MI enhanced the targeting of NGR1 to the infarcted myocardium and improved cardiac function. More importantly, our pioneering research provides a new strategy for targeting drug delivery systems to the ischemic niche.

biochemistry & molecular biology

What problem does this paper attempt to address?

The paper aims to address several key issues in the treatment of Myocardial Infarction (MI). Specifically:

1. **Drug Targeted Delivery Issue**: During myocardial infarction, existing first-line drug treatments mainly focus on slowing the progression of the disease but have limited effects on the reconstruction of damaged myocardial cells. Therefore, developing effective treatment strategies is crucial. The study designed mesoporous silica nanoparticles (MSN) loaded with Notoginsenoside R1 (NGR1) and modified with CD11b antibodies to achieve precise non-invasive targeted delivery to the myocardial injury site.

2. **Oxidative Stress and Myocardial Injury**: Myocardial cell apoptosis is one of the main forms of damage in myocardial infarction, and oxidative stress imbalance is an important factor leading to cell apoptosis. The study found that the production and accumulation of a large amount of Reactive Oxygen Species (ROS) exacerbate myocardial injury. Therefore, controlling oxidative stress is crucial for improving the cardiac function of patients with myocardial infarction.

3. **Bioavailability of NGR1**: Although NGR1 has significant efficacy in cardiovascular diseases, its poor membrane permeability and rapid bile excretion result in extremely low oral bioavailability. By using the mesoporous silica nanoparticle system, the bioavailability of NGR1 can be improved, enhancing its therapeutic effect.

In summary, this paper is dedicated to designing a novel drug delivery system—MSN-NGR1-CD11b antibody nanoparticles—to achieve effective targeted therapy for the myocardial infarction area and to alleviate myocardial injury by improving oxidative stress, ultimately aiming to improve cardiac function. Additionally, the study explores the mechanisms by which NGR1 protects the myocardium through the activation of PI3K/AKT, MAPK, and Hippo signaling pathways.